Orchid Pharma Limited
Orchid Pharma Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹368 cr of revenue in its latest quarter (Q4 FY26) and kept 7.0% of sales as profit.
Healthier than 52% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 81–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 44
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in ORCHPHARMA?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹368 cr |
| Other Income | ₹8 cr |
| Total Income | ₹376 cr |
| Cost of Materials | ₹210 cr |
| Purchases of Stock-in-Trade | ₹47.6 L |
| Inventory Change (±) | ₹35 cr |
| Employee Benefit Expense | ₹28 cr |
| Finance Costs | ₹2 cr |
| Depreciation & Amortisation | ₹11 cr |
| Other Expenses | ₹65 cr |
| Total Expenses | ₹351 cr |
| Exceptional Items | ₹-22 L |
| Profit before Tax | ₹25 cr |
| Tax Expense | ₹0.17 L |
| Share of JV / Associates | ₹99.5 L |
| Net Profit | ₹26 cr |
| Net margin on total income | 6.9% |
| Metric | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|
| Revenue | 194 cr | 207 cr | 368 cr |
| Total income | 204 cr | 213 cr | 376 cr |
| Expenses | 208 cr | 218 cr | 351 cr |
| Profit before tax | -3 cr | -12 cr | 25 cr |
| Tax | 0 cr | 0 cr | 0.17 L |
| Net profit (owners' share) | -6 cr | -13 cr | 26 cr |
| Net margin (owners' share, on revenue) | -3.0% | -6.1% | 7.0% |
| EPS (₹) | -1.13 | -2.49 | 4.31 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,867 | ₹4.48 L cr | 38.6 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,323 | ₹2.47 L cr | 68.7 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,875 | ₹1.65 L cr | 82.0 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,135 | ₹1.13 L cr | 30.4 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,376 | ₹1.11 L cr | 35.2 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,948 | ₹1.05 L cr | 71.5 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,175 | ₹98,113 cr | 55.1 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limited | ₹1,690 | ₹97,243 cr | 23.7 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,098 | ₹95,936 cr | 16.9 | 25.2% | 17.1% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹3 / share | 13 Sep 2012 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.
When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.
As of Mar 2026, the company says it has spent 67% of what it set aside, leaving ₹161 cr still to be spent. Care Ratings Limited watches the spending on the exchange’s behalf.
“In view of changes in the business environment and to meet current strategic requirements, the Company has modified the allocation of the QIP Proceeds. The commencement of “new block at API Facility of the Company in Alathur” project has been postponed to a later stage. Therefore, QIP Proceeds allotted to API Facility in Alathur has been reallocated with the approval of shareholders at the AGM held on September 30, 2025, to mitigate such additional financial burden, improve profit and ensure the best possible utilization of the QIP proceeds in the overall interest of the Company and its shareholders.”the company’s own explanation, as filed · shareholders approved the change
Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing